期刊文献+

酒石酸伐尼克兰片上市包装材料的考察

Investigation on Package Materials for Varenicline Tartrate Tablet
原文传递
导出
摘要 目的筛选酒石酸伐尼克兰片合适的上市包装材料。方法酒石酸伐尼克兰片分别采用双铝包装、聚氯乙烯(PVC)/聚偏二氯乙烯(PVDC)铝塑泡罩包装、Aclar铝塑泡罩包装3种不同包装,进行加速试验考察6个月,在不同时间点检测样品的性状、水分、溶出度、含量和有关物质。结果加速试验6个月,双铝包装中酒石酸伐尼克兰片杂质C和总杂质分别为0.08%和0.13%;PVC/PVDC铝塑泡罩包装中酒石酸伐尼克兰片杂质C和总杂质分别为0.62%和0.78%;Aclar铝塑泡罩包装中酒石酸伐尼克兰片杂质C和总杂质分别为0.31%和0.38%。结论双铝包装的酒石酸伐尼克兰片质量最佳且包装成本相对较低,双铝包装是酒石酸伐尼克兰片的最佳上市包装。 Objective To screen suitable package materials for Varenicline tartrate tablet.Methods Varenicline tartrate tablet were packaged separately with double aluminum,PVC/PVDC,and Aclar aluminum plastic blister,and stored under accelerated condition for 6 months.The appearence,moisture,dissolution,content,and impurity were tested at different periods.Results At the 6 th month of the accelerated test,the impurity C and total impurity of Varenicline tartrate tablet were 0.08%and 0.13%in the double aluminum package.Conclusion The double aluminum packaging of Varenicline tartrate tablet has the best quality and relatively low cost of packaging.Double aluminum packaging is the best packaging for varenicline tartrate tablets.
作者 刘竹 邢涛 肖功胜 魏荣 高昕宇 冯煜 谭红薇 LIU Zhu;XING Tao;XIAO Gong-Sheng;WEI Rong;GAO Xin-Yul;FENG Yu;TAN Hong-Wei(Shaanxi Buchang Pharmaceutical Limited Company,Xianyang 712021,China;Yangling Buchang Pharmaceutical Limited Company,Xianyang 712100,China)
出处 《中国药物经济学》 2021年第6期110-114,128,共6页 China Journal of Pharmaceutical Economics
基金 陕西省重点研发计划一般项目(2019SF-180)。
关键词 酒石酸伐仑克林片 包装材料 稳定性 Varenicline tartrate tablet Package material Stability
  • 相关文献

参考文献5

二级参考文献64

  • 1丁召兴 楮爱武 李娟 等.药品包装材料与药物的关系.中国药事,1995,9(6):372-372.
  • 2Tickner JA,SchettlerT,Guidotti T,et al.Health risks posed by use of Di-2-ethylhexyl phthalate(DEHP)in PVC medical devices:a critical review[J].Am J Ind Med,2001,39(1):100-111.
  • 3Li Q, Hsia J,Yang G.Prevalence of smoking in China in 2010 [J].N Engl J Med,2011 ,364(25):2469-2470.
  • 4中华人民共和国卫生部.中国吸烟危害健康报告[M].北京:人民卫生出版社,2012:1-20.
  • 5A Clinical Practice Guideline Treating Tobacco Use and Dependence2008 Update Panel, Liaisons, and Staff.A Clinical Practice Guide-line for Treating Tobacco Use and Dependence: 2008 Update A U.S.Public Health Service Repor[ J]t.Am J Prev Med,2008 ,35(2):158-176.
  • 6世界卫生组织烟草或健康合作中心,中国疾病预防控制中心控烟办公室,中国控制吸烟协会医院控烟专业委员会.2007年版中国临床戒烟指南(试行本)[M].北京:人民卫生出版社,2007:1-30.
  • 7Coe JW, Brooks PR,Wirtz MC,et al.3 ,5-Bicyclic aryl piperidines: anovel class of alpha4beta2 neuronal nicotinic receptor partial ago-nists for smoking cessation [ J].Bioorg Med Chem Lett, 2005 , 15(22):4889-4897.
  • 8Obach RS,Reed-Hagen AE,Krueger SS,et al.Metabolism and dis-position of varenicline, a selective alpha4beta2 acetylcholine recep-tor partial agonist, in vivo and in vitro [ J].Drug Metab Dispos,2006,34(1):121-130.
  • 9Faessel HM,Smith BJ,Gibbs MA,et al.Single-dose pharmacokinet-ics of varenicline,a selective nicotinic receptor partial agonist,inhealthy smokers and nonsmokers [ J].J Clin Pharmacol,2006,46(9):991-998.
  • 10Burstein AH,Fullerton T,Clark DJ'et al.Pharmacokinetics,safety,and tolerability after single and multiple oral doses of varenicline inelderly smokers [ J].J Clin Pharmacol, 2006 ,46( 11): 1234-1240.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部